

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/965,766	09/28/2001	Helmut Meissner	1/1150	3427	
28501 75	07/15/2002		-		
BOEHRINGER INGELHEIM CORPORATION			EXAMINER		
900 RIDGEBURY ROAD			HUẨNG, EVELYN MEI		
P. O. BOX 368	į				
RIDGEFIELD,	C1 008//		ART UNIT	PAPER NUMBER	
			1625		
	,	DATE MAILED: 07/15/2002 5			

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application	N	Applicant(s)	_		
•							
•	Office Action Summary	09/965,766		MEISSNER ET AL.			
Onice Action Gammary		Examiner		Art Unit			
The MAILING DATE of this communication and		Evelyn Huar		1625			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status							
1)[	Responsive to communication(s) filed on						
2a)[_	This action is <b>FINAL</b> . 2b) 🖂 T	This action is no	on-finai.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
· · ·	n of Claims						
, —	4)⊠ Claim(s) <u>1-40</u> is/are pending in the application.						
	4a) Of the above claim(s) <u>13-18 and 36-40</u> is/are withdrawn from consideration.						
· <u> </u>	5) Claim(s) is/are allowed.						
	6)⊠ Claim(s) <u>1-12 and 19-35</u> is/are rejected.						
	Claim(s) is/are objected to.						
	Claim(s) are subject to restriction and	or election req	uirement.				
Applicatio	•						
·	he specification is objected to by the Examir ne drawing(s) filed on is/are: a)  acc		ciacted to by the Ev	ominor			
10)[1 11			•				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) ☐ All b) ☐ Some * c) ☒ None of:							
,	1.⊠ Certified copies of the priority documents have been received.						
2	2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) The translation of the foreign language provisional application has been received.  15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
1) Notice 2) Notice	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO-1449) Paper No(s)	5	) Notice of Informa	ry (PTO-413) Paper No(s) I Patent Application (PTO-152)			

Application/Control Number: 09/965,766 Page 2

Art Unit: 1625

#### Election/Restrictions

1. Claims 1-40 are pending. Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-12, 19-30, 31-35, drawn to a tropane compound, classified in class 546, subclass 131, the composition comprising the compound as the only active ingredient, and the method of use thereof
- II. Claims 13-18, drawn to a composition comprising multi-active ingredients, classified in class 514, subclass various dependent on the active ingredients.
- III. Claims 36-40, drawn to a diphenyl-carboxylate compound of formula 3, classified in class 560, subclass 101.

The patentability of Group II invention depends on the type and amount of the multiple active ingredients, their interaction, co-action, e.g. synergism etc., which is patentably distinct from the Group I compositions containing only a single active ingredient.

The tropane compound of group I and the diphenyl-carboxylate compound of group II are structurally distinct as shown by their different classification. A reference anticipating group I invention would not render obvious the other groups of invention. The search is therefore not co-extensive and is burdensome. Since the search required for Group I is not required for the other groups, restriction for examination purposes as indicated is proper.

- During a telephone conversation with Mr. Witkowski on 7-10-2002 a provisional election was made without traverse to prosecute the invention of group I, claims 1-12, 19-35.

  Affirmation of this election must be made by applicant in replying to this Office action. Claims 13-18, 36-40 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention.
- 3. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the

Application/Control Number: 09/965,766

Art Unit: 1625

currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

## Claim Rejections - 35 USC § 112

4. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 19-30 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The phrase 'may provide' is indefinite, its replacement with 'provides' is recommended.

#### Claim Rejections - 35 USC § 102

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 6. Claims 1-12, 19-30 are rejected under 35 U.S.C. 102(b) as being anticipated by Banholzer (WO 92/16528, PTO-1449). The compound of Example 8 (page 31, Table V), its composition and its method of use as an anticholinergic agent, are encompassed by the instant claims.
- 7. Claims 31-35 are rejected under 35 U.S.C. 102(b) as being anticipated by Emran. The compounds with RN 172883-93-1 and 172883-99-7, are encompassed by the instant claims 31,

Application/Control Number: 09/965,766

Art Unit: 1625

32. The compounds with RN 172883-95-3 and 172884-00-3, are encompassed by the instant claims 31-35.

8. Claims 31-33 are rejected under 35 U.S.C. 102(b) as being anticipated by Zakharova. The compounds with RN 16658-58-5 and 16658-60-9, are encompassed by the instant claims.

### **Double Patenting**

9. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-12, 19-35 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-11 of copending Application No. 09/976950 in view of Banholzer (WO 92/16528, PTO-1449).

The copending compound has hydrogen, lower alkoxy, lower alkyl or  $-CH_2OH$  whereas the instant has a hydroxy as  $R^7$ . However, in a similar anti-cholinergic compound, Banholzer teaches that hydroxy, hydrogen, lower alkoxy, lower alkyl or  $-CH_2OH$  are all optional choices (page 2, definition of  $R_1$ ). Examples for the various  $R_1$  substituents are shown in Table II and Table V).

One of ordinary skill in the art would be motivated to replace the hydrogen, lower alkoxy, lower alkyl or -CH<sub>2</sub>OH of the copending compound with the alternative, exemplified hydroxy to arrive at the instant invention with the reasonable expectation to obtain an additional compound useful as an anti-cholinergic agent.

Art Unit: 1625

This is a provisional obviousness-type double patenting rejection.

## Conclusion

- 10. No claims are allowed.
- 11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Evelyn Huang whose telephone number is 703-305-7247. The examiner can normally be reached on Tuesday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Alan Rotman can be reached on 703-308-4698. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4556 for regular communications and 703-308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

Evelyn Huang

Primary Examiner
Art Unit 1625

July 11, 2002